Best Healthcare ETFs on the ASX

A Healthcare ETF invests in companies across the healthcare sector including pharmaceuticals, biotechnology, medical devices, health insurers, and hospital operators. On the ASX, DRUG (BetaShares Global Healthcare ETF – Currency Hedged) provides AUD-hedged exposure to global pharma and biotech giants like Eli Lilly, UnitedHealth, Johnson & Johnson, and AbbVie, while IXJ (iShares Global Healthcare) offers broader unhedged exposure including medical device makers like Abbott and Medtronic. Both funds are dominated by US-listed companies given America's outsized share of global healthcare revenue.

The key decision is hedged versus unhedged - DRUG hedges AUD/USD exposure, protecting against a rising Australian dollar but sacrificing gains when the AUD falls, while IXJ leaves currency unhedged, adding another return variable. Compare index methodology, as DRUG tracks a narrower pharma/biotech-focused index while IXJ includes health insurers like UnitedHealth and HCA Healthcare, which behave more like financials. Fees differ (DRUG at 0.67% versus IXJ at 0.46%), and check top-holding concentration - Eli Lilly alone can represent 10%+ of these funds due to its GLP-1 drug-driven market cap surge.

Patent cliffs occur when blockbuster drugs lose patent protection, allowing generic competitors to erode revenues dramatically - AbbVie's Humira lost US exclusivity in 2023, while key patents for drugs from Bristol-Myers Squibb and Merck expire in coming years, threatening billions in revenue. Healthcare ETFs mitigate single-stock patent risk through diversification across 50–100+ holdings, but a cluster of major patent expiries can still drag sector returns as companies scramble to replace lost revenue through M&A or new drug approvals. Investors should check whether their ETF is overweight companies facing near-term patent cliffs or those with strong pipelines like Eli Lilly's GLP-1 obesity franchise.

Healthcare ETFs face FDA approval risk (failed drug trials can crash individual holdings), political risk from drug pricing legislation in the US, and concentration risk in mega-cap pharma that increasingly dominates index weights. However, healthcare is historically a defensive sector that outperforms during recessions due to inelastic demand, and benefits from structural tailwinds like ageing populations in developed economies. These ETFs suit Australian investors seeking diversified offshore defensive exposure - particularly SMSF trustees overweight ASX banks and miners - though distributions are typically unfranked as income comes from US-listed companies subject to foreign withholding tax.